StockData
Lexeo Therapeutics, Inc. logo

Lexeo Therapeutics, Inc. (LXEO) stock

LXEONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$3.23+0.36 (+12.54%)

Close on Nov 16, 2026Market cap $265.01MP/E –Yield –

Lexeo Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Lexeo Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$94.82M. For fiscal 2025 it was -$108.99M.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$108.99M–
FY2024Dec 31, 2024-$105.46M–
FY2023Dec 31, 2023-$68.24M–
FY2022Dec 31, 2022-$60.39M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$27.95M–
Q1 FY2026Mar 31, 2026-$22.26M–
Q4 FY2025Dec 31, 2025-$23.04M–
Q3 FY2025Sep 30, 2025-$21.58M–
Q2 FY2025Jun 30, 2025-$30.63M–
Q1 FY2025Mar 31, 2025-$33.75M–
Q4 FY2024Dec 31, 2024-$27.31M–
Q3 FY2024Sep 30, 2024-$31.46M–
Q2 FY2024Jun 30, 2024-$23.47M–
Q1 FY2024Mar 31, 2024-$23.22M–
Q4 FY2023Dec 31, 2023-$14.90M–
Q3 FY2023Sep 30, 2023-$20.20M–
Q2 FY2023Jun 30, 2023-$13.92M–
Q1 FY2023Mar 31, 2023-$19.23M–
Q4 FY2022Dec 31, 2022-$15.14M–

More Lexeo Therapeutics figures

See a number that looks wrong?